Articles tagged with Glioblastoma Cells
A single injection of an oncolytic virus recruits immune cells to penetrate and persist deep within brain tumors, inducing long-term infiltration of immune T cells. This therapy expands pre-existing T cells in the brain, leading to a therapeutic benefit for patients with glioblastoma.
A bioadhesive patch inspired by mussel adhesion has been developed to eliminate glioblastoma cells. The patch targets remaining cancer cells after surgery, inducing cell death through oxidative stress.
Researchers at the University of Virginia Health System have identified a molecule that blocks the gene responsible for glioblastoma, a fast-growing and deadly brain cancer. The compound shows promise in preventing the invasive cancer from spreading through the brain without causing harm to healthy tissue.
Researchers identified a crucial factor that may help improve treatment for glioblastoma, one of the most aggressive and common forms of adult brain cancer. They discovered a small molecule called miR-181d acts like a master switch that controls how much MGMT is produced by each glioblastoma cell.
Researchers discovered that certain brain cells support glioblastoma growth by sending signals that strengthen the tumour. Blocking this communication slowed the cancer's growth significantly, suggesting an existing HIV medication could be repurposed to treat glioblastoma.
Researchers at UNIGE and HUG have developed CAR-T cells capable of destroying glioblastoma cells by targeting specific proteins present in the tumour environment. The new approach has shown promising results in animal models, paving the way for clinical trials in humans.
Researchers at Virginia Tech's Fralin Biomedical Research Institute are studying how fluid flow contributes to the spread of glioblastoma tumors. They will use focused ultrasound and advanced MRI techniques to build a map of fluid flow in the whole brain and test the effectiveness of drug delivery.
A multi-institutional study found that serially testing tumor samples can detect immune system activation in recurrent glioblastoma even when traditional imaging measures cannot. The researchers used multi-omic analysis and integrated data from various sources to show positive changes in the tumor microenvironment over time.
A Harvard Medical School-led research team developed an AI tool called PICTURE that can reliably tell apart glioblastoma and primary central nervous system lymphoma during surgery. The tool distinguishes between the two cancers with near-perfect accuracy, reducing errors in diagnosis and guiding critical treatment decisions.
Researchers found that glioblastoma cells in clusters are less deadly than those that disperse from these clusters. The dispersed cells are more plastic and resistant to therapy, making them a major contributor to treatment resistance and poor patient outcomes.
A team of Japanese researchers has identified shootin1b as a protein that promotes cell migration in glioblastoma, the most common and difficult-to-treat brain tumor. By suppressing abnormal activity of shootin1b, the study suggests a potential target for preventing glioblastoma spread.
Scientists have found a way to stop brain cancer cells from spreading by 'freezing' hyaluronic acid molecules in place. This approach could lead to a new type of treatment for glioblastoma, the most aggressive form of brain cancer.
Gene coexpression analysis reveals optimal markers of cell types and states, providing opportunities for developing novel biomarkers and targeted treatment strategies for glioma patients. Dr. Oldham's work tackles the reproducibility crisis in science, emphasizing data metadata standardization.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Scientists at Terasaki Institute engineer a novel 3D glioblastoma model that mimics brain tissue and pericyte role, showing increased resistance to chemotherapy. The model increases sensitivity of GBM cell lines to TMZ by 22-32%.
Researchers have developed a new compound, SHP1705, that selectively attacks glioblastoma stem cells by hijacked circadian clock proteins. The compound was found to be safe and well-tolerated in humans during a phase 1 clinical trial.
Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.
Researchers combine radiation with a plant-derived compound to combat glioblastoma, forcing cancer cells into a dormant state. The approach significantly slows tumor growth and improves survival in mice models, offering a potential new avenue for combating this deadly form of brain cancer.
A study suggests targeting endocan, a protein produced by endothelial cells in blood vessels, could slow tumor growth and make glioblastoma more vulnerable to existing treatments. The discovery may lead to new strategies to combat glioblastoma, which has an average lifespan of just 12-15 months.
Research discovered that chloride ion channels play a role in glioblastoma cell division and proliferation. By blocking these channels, replication can be stopped, pointing to ion currents as a potential target for therapeutic approaches.
Scientists at Brain Chemistry Labs discovered a promising compound called kalata B1 from violets that enhances the activity of chemotherapy TMZ against glioblastoma cells. The synthetic version of kalata B1 showed equal efficacy to the natural molecule, offering a potential new treatment option for patients.
A new pathway used by cancer cells to infiltrate the brain has been discovered, offering hope for glioblastoma treatment. Researchers developed a CAR T cell therapy targeting this pathway, showing promise in blocking and killing tumor cells.
Scientists used AI to identify genes that can convert brain cancer cells into immune cells, increasing survival chances by up to 75% in mouse models. The approach bypasses the blood-brain barrier, offering new hope for aggressive cancers.
Researchers have developed a nanosurgical tool that enables them to study individual living cancer cells in real-time, allowing for vital understanding of how they react to treatment and change over time. This breakthrough could lead to more effective cancer medication, particularly for glioblastoma, the deadliest form of brain tumour.
Researchers identified gartisertib as a potent ATR inhibitor that enhances cell death in patient-derived glioblastoma cell lines. The study also showed synergy between gartisertib and TMZ+RT treatment, with higher sensitivity to gartisertib observed in MGMT promoter unmethylated cells.
A new study found that perivascular fibroblasts support the creation of an immunosuppressive tumor microenvironment, allowing glioblastoma to evade the immune system. The fibroblasts may also promote stem-like cancer cells that rarely divide, leading to poor survival outcomes.
Researchers at The Hospital for Sick Children have discovered a designer peptide that targets a previously unknown protein-protein interaction in glioblastoma cells, resulting in the death of tumor cells across all subtypes. The treatment approach showed robust therapeutic efficacy and no side effects in preclinical models.
Research suggests that glioblastoma cells possess large-scale coordination, allowing them to respond unison to therapies. Disrupting this organization may result in more powerful treatments for brain tumors.
A team of researchers has discovered that a naturally produced chemical in the body helps glioblastoma cells go unrecognized by the immune system. The findings could lead to the development of new and more effective treatments for this aggressive brain cancer.
Two compounds, A5 and C1, have shown promising results in inhibiting the growth of glioblastoma cells, a type of aggressive brain cancer. Further research is needed to confirm their effectiveness on normal nerve cells and to move towards clinical trials.
A team of researchers from Korea and USA identified the importance of lipid homeostasis in overcoming brain cancer radioresistance. They found that regulating diacylglycerol kinase B and diacylglycerol acyltransferase 1 could potentially sensitize brain cancer cells to radiotherapy, offering a new treatment strategy.
A team of researchers from Cold Spring Harbor Laboratory has made a breakthrough in understanding the deadly brain cancer glioblastoma. By linking the BRD8 protein to another key protein, P53, they have identified a potential target for new treatments that could extend patient survival and improve outcomes.
A massive collaborative study using federated learning developed a model that enhances identification and prediction of boundaries in three tumor sub-compartments without compromising patient privacy. The dataset, comprising 6,314 glioblastoma patients from 71 sites globally, is the largest and most diverse ever considered.
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
Researchers found that the Klotho gene can suppress glioblastoma cell viability and induce apoptosis, leading to a significant decrease in tumor growth. The study contributes to the development of new diagnostic and treatment approaches for malignant brain tumors.
Researchers found that CBD shrinks glioblastoma tumors by reducing inflammation and restoring immune balance. The compound also suppresses key proteins involved in tumor growth and spread, making it a potential novel adjunct therapy for glioblastoma patients.
Researchers at Tel Aviv University successfully printed the first entirely active and viable glioblastoma tumor using a 3D printer. The 3D-bioprinted model includes functional blood vessels that simulate a real tumor, making it a promising tool for predicting treatment efficacy and drug development.
Researchers at the University of Minnesota identified a new drug target for glioblastoma patients who defy conventional wisdom by surviving beyond expectations. Glioblastoma cells subvert immune system cells called microglia and macrophages, leading to tumor growth.
Researchers at McGill University identified a new cellular pathway controlling cell surface receptor proteins that limits brain tumor growth and spread. Restoring the activity of Rab35, a protein involved in this pathway, may be a new therapeutic strategy for glioblastoma.
Researchers identified a circular RNA, circ2082, and an RNA-binding protein, RBM3, that form a complex with the enzyme DICER to disrupt microRNAome regulation in glioblastoma cells. This leads to increased survival rates in mice and longer lifespans in human patients with circ2082-dependent signatures.
Researchers found that loperamide triggers autophagic cell death in glioblastoma cells by inducing ER stress, opening new avenues for treatment strategies. The mechanism may also be applicable to other diseases where ER degradation is disrupted.
Researchers discovered that immune system T cells can home-in on tumor cells independently of intermediary immune cells and release chemical signals that attract more T cells. This 'swarming' behavior could help develop new cancer therapies targeting solid tumors, currently less responsive to immunotherapies.
Glioblastoma multiforme is the most aggressive brain cancer with low five-year survival rate due to rapid development of radioresistance. Researchers from Hokkaido University and Stanford University identified Rab27b and epiregulin as key molecules contributing to radioresistance.
Researchers at Uppsala University have discovered new ways to combine drugs for glioblastoma patients, tailoring therapy to individual tumours. The study characterised how genetic aberrations influence drug effectiveness, revealing two main subgroups based on response and mutations.
A new imaging technique allows researchers to study 3D printed brain tumors in unprecedented detail, revealing how treatments affect complex tumor cells. This method provides a more accurate evaluation of drug effectiveness than traditional methods, which could lead to improved treatment outcomes for patients with glioblastomas.
Researchers at Texas A&M University have found that the AH receptor can actually block invasion of glioblastoma cells, rather than promoting it. Adding certain ligands to the receptor has been shown to inhibit cell invasion and provide additional protection to the brain.
A recent study using single-cell sequencing has revealed that glioblastoma, a deadly brain cancer, can shift among four distinct cell types, each requiring separate targeted therapy. The findings indicate a need for combination treatments and provide new insights into the cancer's plastic nature.
Researchers found cancer stem cells can change surface markers in response to environmental stressors, making targeted therapies less effective. The study's findings could lead to more optimized treatments by understanding how tumor cells adapt to their microenvironment.
Researchers at University of Helsinki found that MDGI protein plays a key role in regulating lysosomal membrane stability. Inhibiting this protein causes glioblastoma cell death, particularly with antihistamine clemastine, which can cross the blood-brain barrier.
A study at UCSF discovered how a mutation in the TERT promoter gene confers immortality on tumor cells, enabling their aggressive growth. Eliminating a specific protein subunit using CRISPR-based gene editing slowed cancer cell growth.
A recent study reveals that dying glioblastoma cells can communicate with remaining tumor cells through extracellular vesicles, increasing aggressiveness and therapy resistance. This mechanism may provide a new target for novel cancer therapies to treat glioblastoma and potentially other cancer types.
A team of researchers has genetically engineered cancer-killing immune cells to hunt brain tumors displaying CSPG4, a highly prevalent molecular target. The approach holds promise for controlling tumor growth in glioblastoma patients, who currently have limited treatment options with survival benefits of less than a year and a half.
Researchers found that Zika virus infection causes death of glioblastoma cells, a common and aggressive type of brain tumor. The study suggests that genetically modifying Zika virus to produce the digoxin molecule could be an alternative treatment for glioblastoma.
Glioblastoma, a type of brain cancer with a grim prognosis, may be treatable more effectively when administered at specific times of day. Researchers found that the circadian rhythm controls daily rhythms in a key protein associated with tumor growth, and inhibiting its activity can reduce invasive properties.
A study published in Cell Reports found that altering the levels of microRNA miR-128 can induce a more homogeneous subtype of glioblastoma cells, making them more responsive to treatment. This discovery opens the door for using miR-128 as a therapeutic agent.
Scientists have pinpointed two molecules, FOXG1 and SOX2, that drive glioblastoma cells' rapid division and prevent specialization. These findings could lead to the development of new therapies targeting these molecules to slow or stop tumour growth.
Researchers at Uppsala University discovered a correlation between brain tumor cell origin and its growth rate, malignancy, and response to cancer drugs. The study found that tumors originating from immature neural stem cells were more aggressive and less sensitive to treatment than those from differentiated glial cells.